GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders... Show more
GeneDx Holdings Corp. is a genomics company that provides genetic testing and interpretation services focused primarily on pediatric and rare-disease diagnostics through whole exome and whole genome sequencing. Its medium-term positioning rests on a powerful flywheel: a vast, proprietary clinical dataset that improves diagnostic accuracy, which in turn attracts more clinicians and generates more data.
The company has reported roughly 80% market share among geneticists and strong brand recognition among pediatric specialists. Management is now systematically moving down the adoption curve, targeting general pediatricians, maternal-fetal medicine specialists, adult neurologists, and NICU teams. The June 2025 American Academy of Pediatrics recommendation elevating exome and genome sequencing to first-tier status for children with developmental delay or intellectual disability meaningfully widens the company's addressable market. Recent FDA Breakthrough Device designations for its ExomeDx and GenomeDx tests further reinforce its clinical credibility.
Structurally, the company's expansion strategy is deliberately stacked rather than dependent on a single bet, layering foundational markets with ramping and future markets such as genomic newborn screening, telemedicine channels, and biopharma data partnerships.
Several near-term developments could shape investor sentiment. The next earnings report is a focal point, offering a read on whether exome and genome volume growth remains in the targeted 33% to 35% range and whether adjusted profitability holds despite product-mix shifts toward genome sequencing. Management has signaled that general-pediatric volumes should begin to pick up in the fourth quarter of 2026 as its dedicated sales force matures.
The rollout of GenomeDx Prenatal, a whole genome sequencing test for pregnancies with fetal anomalies identified on ultrasound, represents a meaningful entry into a sizable new market. Likewise, participation in the NIH-funded BEACONS multi-state genomic newborn screening initiative and a state-backed program in Florida position the company for the longer-term genomic newborn screening opportunity. The acquisition of Fabric Genomics extends interpretation capabilities internationally, while the Komodo Health partnership enriches the Infinity dataset.
On the analyst front, sentiment has been constructive but calibrating. Wells Fargo upgraded the stock to Overweight in early 2026, while other firms such as Piper Sandler lowered their targets to reflect tempered margin expectations. As of late 2026, the consensus recommendation remains a "Strong Buy" according to several aggregators, with an average 12-month price target in the high-$80s to low-$90s range across a relatively small set of covering analysts. The direction of future revisions will likely hinge on reimbursement stability and the pace of new-market adoption.
The company's outlook is closely tied to healthcare policy and payer economics rather than broad consumer cycles. Reimbursement expansion is a core driver: state Medicaid programs progressively adopting coverage for exome and genome sequencing directly enlarges the insurable patient base. Higher interest rates have a comparatively modest direct effect on GeneDx's operations, but the valuation of high-growth, mostly unprofitable companies on a generally accepted accounting principles (GAAP) basis tends to be more sensitive to rate expectations than established cash generators.
Technology adoption trends are favorable, as the cost of sequencing continues to decline and AI-assisted interpretation reduces turnaround times. Inflation in labor and reagent costs could pressure margins, although the company has demonstrated an ability to lower its cost curve with scale. Regulatory climate is a net positive given federal support for newborn screening initiatives, though any slowdown in state-level coverage decisions would temper growth.
Investors seeking an additional analytical lens can turn to Tickeron's Trend Prediction Engine, an AI-powered forecasting tool designed to help traders identify whether a stock, exchange-traded fund, or other asset may trend bullish, bearish, or sideways over the next week or month. The engine aims to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments, with searchable prediction categories, historical context, and alert-oriented functionality. Whether you are tracking GeneDx specifically or surveying the broader genomics and healthcare landscape, the Trend Prediction Engine offers a neutral, data-driven complement to fundamental analysis.
Looking toward 2026 and beyond, GeneDx's trajectory hinges on its ability to convert a broad clinical mandate into sustained, profitable volume growth. Management's 2026 guidance calls for $540 million to $555 million in revenue, exome and genome volume growth of 33% to 35%, and positive adjusted net income. The strategic emphasis is on expanding clinician penetration while maintaining adjusted gross margins at or above 70%.
Long-term themes include the transition from exome to genome sequencing as costs decline, the potential scale-up of genomic newborn screening into routine care, and the monetization of a uniquely deep rare-disease dataset for biopharma and precision medicine. Margin sustainability will depend on reimbursement trends and continued automation. Competitive threats from other large genomics laboratories remain relevant, but GeneDx's data advantage and clinical brand provide a durable moat. Capital allocation is focused on sales-force expansion and technology rather than near-term returns, which means profitability gains are expected to build gradually into 2027 and beyond.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, WGS has been loosely correlated with COIN. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if WGS jumps, then COIN could also see price increases.
| Ticker / NAME | Correlation To WGS | 1D Price Change % | ||
|---|---|---|---|---|
| WGS | 100% | -7.68% | ||
| COIN - WGS | 59% Loosely correlated | -6.34% | ||
| CLSK - WGS | 53% Loosely correlated | -16.27% | ||
| RIOT - WGS | 50% Loosely correlated | -8.46% | ||
| NEO - WGS | 39% Loosely correlated | -1.79% | ||
| ADPT - WGS | 38% Loosely correlated | -0.43% | ||
More | ||||
| Ticker / NAME | Correlation To WGS | 1D Price Change % |
|---|---|---|
| WGS | 100% | -7.68% |
| Medical Specialties category (43 stocks) | 30% Poorly correlated | -3.22% |
| Medical Specialties category (43 stocks) | 30% Poorly correlated | -3.22% |
Industry MedicalSpecialties
The Aroon Indicator for WGS entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 232 similar instances where the Aroon Indicator formed such a pattern. In 217 of the 232 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on WGS as a result. In 66 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for WGS turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where WGS's RSI Indicator exited the oversold zone, 29 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where WGS advanced for three days, in 233 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
WGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.616) is normal, around the industry mean (67.298). P/E Ratio (-17.182) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.270) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. WGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.